X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
JDMFs Filed
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
Canada
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
1. Disodium Borate, Heptahydrate
2. Disodium Borate, Monohydrate
3. Komex
4. Monosodium Metaborate
5. Sodium Borate
6. Sodium Borate (nabo2)
7. Sodium Diborate
8. Sodium Meta Borate
9. Sodium Metaborate
1. 1330-43-4
2. Borax Anhydrous
3. Borax Glass
4. Borax, Fused
5. Boric Acid (h2b4o7), Sodium Salt
6. Boron Sodium Oxide (b4na2o7)
7. Na2b4o7
8. Sodium Tetraborate, Anhydrous
9. Sodiumtetraborate
10. Sodium Borate Anhydrous
11. Anhydrous Borax
12. Sodium Biborate
13. Fused Borax
14. Sodium Pyroborate
15. Sodium Borate, Anhydrous
16. 8191en8zmd
17. Sodium Tetraborate (na2b4o7)
18. Mfcd00081185
19. Boric Acid (h2b4o7), Disodium Salt
20. Disodium;3,7-dioxido-2,4,6,8,9-pentaoxa-1,3,5,7-tetraborabicyclo[3.3.1]nonane
21. 12267-73-1
22. Disodium;[oxido(oxoboranyloxy)boranyl]oxy-oxoboranyloxyborinate
23. Mfcd00163147
24. Komex
25. Borax, Anhydrous
26. Borax, Dehydrated
27. Sodium Boron Oxide
28. Rasorite 65
29. Fused Sodium Borate
30. Boric Acid, Disodium Salt
31. Sodium Borate [mi]
32. Unii-8191en8zmd
33. Borate-buffered Saline (5x)
34. Sodium Borate [who-dd]
35. Hsdb 5025
36. Sodium Tetraborate [hsdb]
37. Dtxsid101014358
38. Fr 28
39. Sodium Tetraborate [vandf]
40. Einecs 215-540-4
41. Mfcd07784974
42. Borates, Tetrasodium Salts, Anhydrous
43. Akos015903865
44. Akos030228253
45. Db14505
46. Borates, Tetra, Sodium Salts, Anhydrous
47. Borate, 0.5m Buffer Solution, Ph 8.0
48. Borate, 0.5m Buffer Solution, Ph 8.5
49. Borate, 0.5m Buffer Solution, Ph 9.0
50. Borate, 0.5m Buffer Solution, Ph 9.5
51. Sodium Tetraborate, Anhydrous, Puratronic
52. Ft-0696539
53. Sodium Borate, 0.5m Buffer Solution, Ph 8.0
54. Sodium Borate, 0.5m Buffer Solution, Ph 8.5
55. Sodium Borate, 0.5m Buffer Solution, Ph 9.0
56. Sodium Tetraborate,trace Metals Grade 99.95%
57. J-006292
58. Disodium Bicyclo[3.3.1]tetraboroxane-3,7-bis(olate)
59. 1310383-93-7
| Molecular Weight | 201.2 g/mol |
|---|---|
| Molecular Formula | B4Na2O7 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 0 |
| Exact Mass | 201.9811616 g/mol |
| Monoisotopic Mass | 201.9811616 g/mol |
| Topological Polar Surface Area | 92.3 Ų |
| Heavy Atom Count | 13 |
| Formal Charge | 0 |
| Complexity | 121 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 3 |
MEDICATION (VET): Has been used as antiseptic, detergent, astringent for mucous membrane
O'Neil, M.J. (ed.). The Merck Index - An Encyclopedia of Chemicals, Drugs, and Biologicals. 13th Edition, Whitehouse Station, NJ: Merck and Co., Inc., 2001., p. 1537
MEDICATION (VET): Has been used as an exptl growth promoter in poultry feeds.
Rossoff, I.S. Handbook of Veterinary Drugs. New York: Springer Publishing Company, 1974., p. 50
/Exptl Ther:/ The in vivo spermicidal action of a pharmacological association consisting of 0.080 g of sodium tetraborate decahydrate, 0.075 g lactic acid, 0.020 g 8-hydroxyquinoline sulphate, 0.005 g sodiopropionate, and hydrosoluble excipient 1820 g polyethylene glycol in the form of vaginal containers, has been investigated. The study is part of a more general investigation of alternative systems to the use of estro-progestins. The experimental scheme applied in the present study provided for the use of this association in 28 volunteer couples who were definitely fertile and during the pre- and postovulatory periods. A normal postcoital test was carried out on each, with samples taken from the posterior fornix and cervical canal using a speculum. The results showed that the preparation possesses profound spermicidal activity and is therefore considered a useful alternative to oral contraceptives. /Sodium tetraborate decahydrate/
PMID:6787483 Oriz C et al; Minerva Ginecol 33 (1): 113-6 (1981)
No FDA- or EMA-approved therapeutic indications on its own.
Boric acid exhibits minimal bacteriostatic and antifungal activities. Boric acid is likely to mediate antifungal actions at high concentrations over prolonged exposures.
Absorption
Boric acid is well absorbed from the gastrointestinal tract, open wounds, and serous cavities but displays limited absorption in intact skin. Following intraperitoneal injection in mice, the peak concentration was reached in about 1.0-1.5 hr in the brain whereas the value was 0.5 hr in other tissues.
Route of Elimination
Regardless the route of administration, boric acid predominantly undergoes rapid renal excretion of >90% of total administered dose as unchanged form. Small amounts are also excreted into sweat, saliva, and feces. Following administration as ointment, urinary excretion of boric acid accounted for only 1% of the administered dose.
Volume of Distribution
Volume of distribution ranges from 0.17 to 0.5 L/kg in humans, where large amounts of boric acid are localized in brain, liver, and kidney.
Clearance
A case report of acute boric acid poisoning following oral ingestion of 21 g of boric acid presents the total body clearance of 0.99 L/h before hemodialysis.
The pharmacokinetics of boron was studied in rats by administering a 1 mL oral dose of sodium tetraborate solution to several groups of rats (n=20) at eleven different dose levels ranging from 0-0.4 mg/100 g bw as boron. Twenty-four-hour urine samples were collected after boron administration. After 24 hr the average urinary recovery rate for this element was 99.6-7.9. The relationship between boron dose and excretion was linear (r=0.999) with a regression coefficient of 0.954. This result suggests that the oral bioavailability (F) of boron was complete. Another group of rats (n=10) was given a single oral /intubation/ of 2 mL of sodium tetraborate solution containing 0.4 mg of boron/100 g bw. The serum decay of boron was followed and found to be monophasic. The data were interpreted according to a one-compartment open model. The appropriate pharmacokinetic parameters were estimated as follows: absorption half-life, t1/2a=0.608-0.432 hr; elimination half-life, t1/2=4.64-1.19 hr; volume of distribution, Vd=142.0-30.2 mL/100 g bw.; total clearance, Ctot=0.359 - 0.0285 mL/min/100 g bw. The maximum boron concentration in serum after administration (Cmax) was 2.13-0.270 mg/L, and the time needed to reach this maximum concentration (Tmax) was 1.76-0.887 hr. ...Results suggest that orally administered boric acid is rapidly and completely absorbed from the gastrointestinal tract into the blood stream. Boric acid in the intravascular space does not have a strong affinity to serum proteins, and rapidly diffuses to the extravascular space in proportion to blood flow without massive accumulation or binding in tissues. The main route of boron excretion from the body is via glomerular filtration. It may be inferred that there is partial tubular resorption at low plasma levels.
PMID:9765061 Usuda K et al; Arch Toxicol 72 (8): 468-74 (1998)
/Ten/ rats (n=10) were given a single oral injection of 2 mL of sodium tetraborate solution containing 0.4 mg of boron/100 g bw. The serum decay of boron was followed and found to be monophasic. The data were interpreted according to a one-compartment open model. The appropriate pharmacokinetic parameters were estimated as follows: absorption half-life, t1/2a=0.608-0.432 hr; elimination half-life, t1/2=4.64-1.19 hr; volume of distribution, Vd=142.0-30.2 mL/100 g bw.; total clearance, Ctot=0.359 - 0.0285 mL/min/100 g bw. The maximum boron concentration in serum after administration (Cmax) was 2.13-0.270 mg/L, and the time needed to reach this maximum concentration (Tmax) was 1.76-0.887 hr. ...Results suggest that orally administered boric acid is rapidly and completely absorbed from the gastrointestinal tract into the blood stream. Boric acid in the intravascular space does not have a strong affinity to serum proteins, and rapidly diffuses to the extravascular space in proportion to blood flow without massive accumulation or binding in tissues. The main route of boron excretion from the body is via glomerular filtration. It may be inferred that there is partial tubular resorption at low plasma levels.
PMID:9765061 Usuda K et al; Arch Toxicol 72 (8): 468-74 (1998)
Excretion occurs primarily in the urine.
Sheftel, V.O.; Indirect Food Additives and Polymers. Migration and Toxicology. Lewis Publishers, Boca Raton, FL. 2000., p. 852
No metabolic pathways reported.
According to human cases of poisoning, the elimination half-life of boric acid ranges from 13 to 24 hours.
Information regarding the mechanism of action of boric acid in mediating its antibacterial or antifungal actions is limited. Boric acid inhibits biofilm formation and hyphal transformation of _Candida albicans_, which are critical virulence factors. In addition, arrest of fungal growth was observed with the treatment of boric acid.
Market Place
